Advanced search
Publication Cover
Clinical Ophthalmology Volume 13, 2019 - Issue
Submit an article Journal homepage
241
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

Darrell E White1 Department of Ophthalmology, SkyVision Centers, Westlake, OH44145, USA
,
Yang Zhao2 Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ08540, USACorrespondence[email protected]
,
Abayomi Ogundele2 Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ08540, USA
,
Nicole Fulcher3 Outcomes Research, IBM Watson Health, Cambridge, MA02142, USA
,
Annabel Acs3 Outcomes Research, IBM Watson Health, Cambridge, MA02142, USA
,
Laura Moore-Schiltz3 Outcomes Research, IBM Watson Health, Cambridge, MA02142, USA
&
Paul M Karpecki4 Corneal Services and Advanced OSD Clinic, University of Pikeville Kentucky College of Optometry, Pikeville, KY41501, USA
 show all
Pages 2285-2292 | Published online: 22 Nov 2019

References

  • Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of diagnosed dry eye disease in the united states among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90–98. doi:10.1016/j.ajo.2017.06.033
  • The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92. doi:10.1016/S1542-0124(12)70081-2
  • Dana R, Bradley JL, Guerin A, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019. [ePub ahead of print]. doi:10.1016/j.ajo.2019.01.026
  • Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269–275. doi:10.1016/j.jtos.2017.05.005
  • Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584–589. doi:10.1097/00003226-199811000-00002
  • Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care. 2008;14(3 Suppl):S79–S87.
  • Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409–415. doi:10.1016/j.ajo.2006.11.060
  • Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900–907. doi:10.1097/01.ico.0000214802.40313.fa
  • Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
  • Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 study group. Ophthalmology. 2000;107(4):631–639. doi:10.1016/S0161-6420(99)00176-1
  • Xildra Package insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf. Accessed August 27, 2018.
  • Hugtenburg JG, Timmbers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants and causes of nonadherences with medication: a challenge to tailored interventions. Patient Prefer Adherence. 2013;7:8.
  • Stonecipher KG, Chia J, Onyenwenyi A, Villanueva L, Hollander DA. Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients. Ther Clin Risk Manag. 2013;9:409–415. doi:10.2147/TCRM.S49754
  • Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010;26(2):157–164. doi:10.1089/jop.2009.0091
  • Rao SN. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. J Ocul Pharmacol Ther. 2011;27(6):603–609. doi:10.1089/jop.2011.0073
  • Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: physician’s evaluation of restasis® satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971. doi:10.2147/OPTH.S30261
  • Baudouin C. Detrimental effects of preservatives in eye drops: implications for the treatment of glucoma. Acta Ophthamologica. 2008;86(7):716–726. doi:10.1111/j.1755-3768.2008.01250.x
  • Galor A, Zheng DD, Arheart KL. Dry eye medication use and expendtures: data from the medical expenditure panel survey 2001–2005. Cornea. 2012;31:1403–1407. doi:10.1097/ICO.0b013e31823cc0b7
  • Blumberg DM, Prager AJ, Liebmann JM, Cioffi GA, De Moraes CG. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of medicare part D. JAMA Ophthalmol. 2015;133(9):985–996. doi:10.1001/jamaophthalmol.2015.1671
  • Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115(8):1320–1327, 1327.e1321–1323. doi:10.1016/j.ophtha.2007.11.023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.